BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 14, 2025
See today's BioWorld Asia
Home
» Japan's Peptidream partners with Kleo Pharmaceuticals to develop IO therapies
To read the full story,
subscribe
or
sign in
.
Japan's Peptidream partners with Kleo Pharmaceuticals to develop IO therapies
Aug. 2, 2017
By
Haky Moon
No Comments
HONG KONG – Tokyo-based Peptidream Inc. is partnering with New Haven, Conn.-based Kleo Pharmaceuticals Inc. to develop immuno-oncology (IO) products in multiple indications.
BioWorld Asia
